Ebola trials under way in Bunia: first Bundibugyo-specific vaccines to be tested during an outbreak, WHO says
Clinical trials are running at the epicentre of the Bundibugyo Ebola outbreak in Bunia, eastern DR Congo, where the World Health Organization says 10,668 confirmed cases and 5,198 deaths had been reported by 3 November. The Tumaini trial, launched on 23 October, is testing whether the Ervebo vaccine — licensed against the Zaire species — also protects against Bundibugyo, and WHO expert groups have recommended adding the first two vaccines designed specifically for Bundibugyo, from Oxford/Serum Institute and Moderna, once national approvals are given. A separate treatment trial is testing a monoclonal antibody, an antiviral, and the two together. No vaccine or treatment is yet proven against Bundibugyo.
Checking in progress
This story is still being checked. Claims below are published as claims — never dressed as facts — and each one moves only when the evidence earns it.
- Collecting reportsDone
- Grouping the versionsDone
- Checking claims4 of 4 claims checked
- 4Human gateWe are here
4 of 4 claims checked so far · step 4 of 4: Human gate
Key points
- WHO's count at 3 November: 10,668 confirmed Bundibugyo cases and 5,198 deaths in the DRC — the country's largest Ebola outbreak.
- Tumaini, launched 23 October in Bunia, tests Ervebo against Bundibugyo; Oxford/Serum and Moderna Bundibugyo-specific candidates are recommended to join it.
- MSF's BRAVO study is following up to 20,000 vaccinated frontline workers; the PARTNERS trial tests two treatments and their combination.
Show more (1)
- Nothing is proven yet: vaccine results are expected in early 2027, and no candidate is approved against Bundibugyo.
What happened
Bundibugyo is the rare Ebola species behind this outbreak, declared on 15 May. The vaccines and treatments proven against the Zaire species — the cause of most past outbreaks — have never been shown to work against it, which is why four studies are running at once in and around Bunia, the outbreak's epicentre.
Cases in Bunia itself fell from late September and MSF's treatment centre there closed in October, while transmission flared in North Kivu and Haut-Uele; the treatment trial is preparing new sites at Beni as it follows the virus.
What we know / what we don't know yet
What we know
- The outbreak's size on WHO's count (10,668 cases, 5,198 deaths at 3 November) and the design and status of the four studies, from WHO's and MSF's own accounts and Le Monde's reporting from Bunia.
What we don't know yet
- Whether Ervebo protects against Bundibugyo, and whether the Oxford and Moderna candidates are safe and effective — the trials are designed to answer this, with vaccine results expected in early 2027.
- When the two Bundibugyo-specific candidates will receive national approvals and enter Tumaini.
- Whether the PARTNERS treatments improve survival — early findings are expected in the coming months, and none has been announced.
Claim by claim
Show all claims (4)
Why this label: The figures are the World Health Organization's, from its Disease Outbreak News of 6 November. They are the health authorities' confirmed counts, carried as such.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The trial's design, leadership, launch date and the recommendation are the WHO's own account in its 4 November release and its 6 November Disease Outbreak News. The two new candidates are recommended, not yet approved or proven.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: BRAVO's design and target are MSF's own account; the recruitment figure and the results timing are Le Monde's field reporting from the trial sites, quoting the study's coordinators.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The PARTNERS design is the WHO's own account; the 755 figure and the caution are Le Monde's reporting from the Bunia treatment centre, quoting the doctor hosting the study. No effectiveness finding has been announced for any candidate.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why it matters
Nearly half of confirmed patients in this outbreak have died, with no proven vaccine or treatment for the species causing it. These trials are the first attempt to generate that evidence during an outbreak itself — their results will decide what the next Bundibugyo response can actually use.
Background
Show the background timeline (5)
The Bundibugyo Ebola outbreak is officially declared in the DR Congo.
The PARTNERS treatment trial begins testing MBP134, remdesivir and their combination in confirmed patients.
MSF launches the BRAVO study of Ervebo among frontline workers in Bunia.
The Tumaini vaccine trial enrols its first participants in Bunia.
WHO expert groups recommend adding the Oxford/Serum and Moderna Bundibugyo-specific candidates to Tumaini.
Update history
No silent edits. Every change is written here, with its time.
- Latest
Published in Checking state — the trials and the outbreak figures are confirmed by their owners' accounts, and every candidate's effectiveness is still unproven.